Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback